Neogen Faces Shareholder Investigation Following FDA HYCOAT Recall

A sharp 7.22% intraday decline in Neogen Corporation shares has triggered a formal investigation by the law firm Levi & Korsinsky. The probe examines whether the company misled investors regarding product-quality risks associated with HYCOAT, an equine product later linked to fungal contamination and significant animal mortality.

Money Talk·September 30, 2026·reads: 166

The investigation centers on the timeline of disclosures concerning the Neogen Vet line. FDA testing of HYCOAT, which was marketed as a sterile product, revealed multiple fungal species. Reports surrounding the recall indicate that nearly 100 horses were affected by the contamination, with at least 20 deaths documented. Shareholders are now questioning if management provided accurate information about safety and quality protocols before the regulatory warning caused the stock value to plummet on September 30, 2026.

Levi & Korsinsky is seeking to determine if Neogen violated securities laws by issuing allegedly false or misleading statements that kept stock prices artificially inflated. The firm is currently evaluating potential recovery options for investors who purchased shares prior to the public disclosure of the FDA warning. This inquiry remains active ahead of the company's next quarterly earnings report, scheduled for October 6, 2026. Legal representatives note that eligibility for potential compensation extends to both current and former shareholders who incurred losses during the period in question.